Quarterly report pursuant to Section 13 or 15(d)

Goodwill and Other Intangible Assets (Tables)

v3.21.1
Goodwill and Other Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets Carrying Value

The net carrying value of the identifiable intangible assets from all acquisitions as of March 31, 2021 and December 31, 2020 are as follows:

 

        As of March 31, 2021     As of December 31, 2020  
    Life   Carrying     Carrying  
    (Years)   Amount     Amount  
        (unaudited)        
Asuragen acquisition:                    
Thyroid   9   $ 8,519     $ 8,519  
RedPath acquisition:                    
Pancreas test   7     16,141       16,141  
Barrett’s test   9     6,682       6,682  
BioPharma acquisition:                    
Trademarks   10     1,600       1,600  
Customer relationships   8     5,700       5,700  
                     
CLIA Lab   2.3   $ 609     $ 609  
                     
Total       $ 39,251     $ 39,251  
                     
Accumulated Amortization       $ (29,013 )   $ (27,900 )
                     
Net Carrying Value       $ 10,238     $ 11,351  

Schedule of Future Estimated Amortization Expense

Estimated amortization expense for the next five years is as follows:

 

2021     2022     2023     2024     2025  
                           
$ 4,078     $ 2,155     $ 2,099     $ 873     $ 873  
Schedule of Goodwill Carrying Value

The following table displays a roll forward of the carrying amount of goodwill from December 31, 2020 to March 31, 2021:

 

    Carrying  
    Amount  
Balance as of December 31, 2020   $ 8,433  
Adjustments     -  
Balance as of March 31, 2021   $ 8,433